Related Experiment Video
Updated: Jun 18, 2026

Applying an Inducible Expression System to Study Interference of Bacterial Virulence Factors with Intracellular Signaling
Published on: June 25, 2015
Inhibition of the ER Ca2+ pump forces multidrug-resistant cells deficient in Bak and Bax into necrosis
Katja Janssen1, Sibylle Horn, Mathis T Niemann
1Interfaculty Institute for Biochemistry, University of Tübingen, Tübingen, Germany.
Abstract:
Tumor cells deficient in the proapoptotic proteins Bak and Bax are resistant to chemotherapeutic drugs. Here, we demonstrate that murine embryonic fibroblasts deficient for both Bak and Bax are, however, efficiently killed by thapsigargin, a specific inhibitor of ER Ca(2+) pumps that induces ER stress by depleting ER Ca(2+) stores. In the presence of Bak and Bax, thapsigargin eliminates cells by release of mitochondrial cytochrome c and subsequent caspase activation, which leads to the proteolytic inactivation of the molecular necrosis switch PARP-1 and results in apoptosis. By contrast, in the absence of Bak and Bax, a failure to activate caspases results in PARP-1-mediated ATP depletion. The subsequent necrosis is not prevented by autophagy as an alternative energy source. Moreover, in cells deficient for both Bak and Bax, thapsigargin induces permanent mitochondrial damage by Ca(2+) overload, permeability transition and membrane rupture. Thus, even though deficiency in Bak and Bax protects these cells against apoptosis, it does not compromise necrosis induced by SERCA inhibitors. Importantly, thapsigargin induces caspase-independent cell death also in colon and prostate carcinoma cells deficient in Bak and Bax expression. Therefore, targeted application of ER stressors such as thapsigargin might be a promising approach for the treatment of Bak- and Bax-deficient, drug-resistant tumors.
Insights
Thapsigargin, an ER stress inducer, effectively kills cancer cells lacking Bak and Bax proteins, bypassing apoptosis resistance. This suggests thapsigargin as a potential treatment for drug-resistant tumors.
Area of Science:
- Cellular Biology
- Molecular Oncology
- Drug Discovery
Background:
- Tumor cells lacking Bak and Bax are resistant to chemotherapy.
- Understanding alternative cell death pathways is crucial for cancer treatment.
Purpose of the Study:
- To investigate the efficacy of thapsigargin in Bak and Bax-deficient cancer cells.
- To elucidate the cell death mechanisms induced by thapsigargin in the absence of Bak and Bax.
Main Methods:
- Utilized murine embryonic fibroblasts and human colon/prostate carcinoma cells.
- Administered thapsigargin, an ER Ca(2+) pump inhibitor.
- Assessed apoptosis, necrosis, caspase activation, PARP-1 activity, and mitochondrial integrity.
Main Results:
- Thapsigargin induces necrosis, not apoptosis, in Bak/Bax-deficient cells.
- Cell death occurs via PARP-1-mediated ATP depletion and mitochondrial damage.
- Thapsigargin effectively kills Bak/Bax-deficient colon and prostate cancer cells.
Conclusions:
- Bak and Bax deficiency confers resistance to apoptosis but not to thapsigargin-induced necrosis.
- ER stress inducers like thapsigargin represent a promising therapeutic strategy for Bak/Bax-deficient, drug-resistant tumors.
Related Concept Videos
Necrosis
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become anucleated and die, but their...
The Intrinsic Apoptotic Pathway
Cellular Injury IV: Necrosis
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and pro-apoptotic...
The Extrinsic Apoptotic Pathway
Cellular Injury V: Apoptosis and Autophagy
